Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 5/20 | 0.56 |
| ▸ | RAB9A | P51151 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | ME2 | P23368 | 1/20 | 0.54 |
| ▸ | ME1 | P48163 | 1/20 | 0.54 |
| ▸ | ME3 | Q16798 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL333807 | 0.83 | NPC1 (0.61) | MAPTKDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL12994627 | 0.80 | CA12 (0.76) | MAPTKDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL5508987 | 0.79 | MAPT (0.77) | MAPTKDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL598858 | 0.79 | MAPT (0.81) | MAPTKDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL26758591 | 0.79 | MAPT (0.84) | MAPTKDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL5525070 | 0.77 | MAPT (0.69) | MAPTKDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL22601218 | 0.77 | MAPT (0.76) | MAPTKDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL6074926 | 0.76 | RAB9A (0.61) | MAPTKDM4ENPC1RAB9AL3MBTL1 | |
| SCHEMBL334490 | 0.76 | NPC1 (0.61) | MAPTKDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL11889846 | 0.76 | ME2 (0.82) | MAPTKDM4ENPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108603-A1 | AMINOCARBONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-05-03 | — | — | US | disclosed |
| US-8114999-B2 | Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-02-14 | — | — | US | disclosed |
| US-20100048588-A1 | AMINOCARBONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | VAN EMELEN KRISTOF | 2010-02-25 | — | — | US | disclosed |
| EP-1485364-B1 | AMINOCARBONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA NV (BE) | 2009-03-11 | — | — | EP | disclosed |
| US-7501417-B2 | N-(4-methylphenyl)-4-[4-[[(phenylmethoxy)amino]carbonyl]phenyl]-1-piperazinecarboxamide; anticarcinogenic, antiproliferative agent; ovarian carcinoma, psoriasis; gene transcription control | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-03-10 | — | — | US | disclosed |
| US-20050222414-A1 | N-(4-methylphenyl)-4-[4-[[(phenylmethoxy)amino]carbonyl]phenyl]-1-piperazinecarboxamide; anticarcinogenic, antiproliferative agent; ovarian carcinoma, psoriasis; gene transcription control | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-10-06 | — | — | US | disclosed |
| EP-1485364-A1 | AMINOCARBONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003076421-A1 | AMINOCARBONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222414-A1 | N-(4-methylphenyl)-4-[4-[[(phenylmethoxy)amino]carbonyl]phenyl]-1-piperazinecarboxamide; anticarcinogenic, antiproliferative agent; ovarian carcinoma, psoriasis; gene transcription control | RELA, NFE2, HDAC1 | MAPT 3978/4885KDM4E 89/4885NPC1 4417/4885 |
| US-20100048588-A1 | AMINOCARBONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC3, HDAC11 | MAPT 3726/4885KDM4E 67/4885NPC1 2563/4885 |
| US-20120108603-A1 | AMINOCARBONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC3, HDAC11 | MAPT 3726/4885KDM4E 67/4885NPC1 2563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.